Start Here
Healthcare Reform: The Big Questions
Why does American healthcare cost what it does? Why does reform keep falling short? And what does the evidence actually say would work? This page is a map of the investigation — the big questions, answered briefly, each linking to the full reporting behind it.
Why is American healthcare so expensive?
The United States spends roughly twice per person what comparable wealthy nations spend, without consistently achieving better health outcomes for the money. The explanation isn't a single villain — it's the shape of the whole system: a fragmented multi-payer structure, a "denial machine" that reverses itself roughly four times out of five on appeal, and decades of consolidation that concentrated market power in fewer, larger hands while private equity moved in behind it.
Why do prescription drugs cost so much in America?
Because federal law treats Medicare and the VA differently. A single sentence in a 2003 law bars Medicare from negotiating most drug prices; a different statute lets the VA negotiate freely — and the VA pays roughly 54% less than Medicare for the same medicines as a direct result. A pharmacy benefit manager most Americans have never heard of stands behind nearly every prescription filled in the country, often owned by the same corporate family as the insurer paying the claim.
Who profits from American healthcare?
Insurers, pharmacy benefit managers, hospital systems, pharmaceutical manufacturers, and increasingly private equity firms each earn money at a different link in the chain between a patient and their care. Naming who profits isn't an accusation that every participant acts improperly — it's the first step in understanding why the incentives in American healthcare are shaped the way they are.
Has science and public health become politicized?
Two investigations trace this from different directions. One asks how public trust in the CDC collapsed during COVID-19 — a 27-point drop in a single year — while holding institutions and their critics to the same evidentiary standard. The other documents what happened after: the rapid 2025 restructuring of the NIH, CDC, and HHS, and the public-health consequences already on the record, including the return of measles deaths for the first time in a decade.
What would replace the current system?
The evidence assembled across this site points toward single-payer financing — not as an imported foreign idea, but modeled in part on a system the U.S. already runs: the VA, which delivers care at lower cost with measurably better outcomes on several key measures than private-sector alternatives. At the state level, that idea already has a drafted bill: the Washington Health Trust, a specific piece of legislation designed as a working Phase One prototype.
Why has healthcare reform repeatedly failed to fix these problems?
Two consistent answers recur across this site's reporting. The first is structural: reform after reform has repaired individual parts of the system — a new rule here, a narrower negotiation there — without addressing the underlying architecture, the way a new roof doesn't fix a cracked foundation. The second is political: the pharmaceutical and health-products industry remains the largest single spender on federal lobbying of any American industry, a permanent, well-funded force behind the status quo. Neither explanation excuses the outcome. Both help explain why partial fixes keep producing partial results.
“We do not need to invent a new system. We need to connect the one we already run for veterans to the one we run for everybody else.”— Rigged at the Counter
What the evidence points toward
Across every book and guide on this site, the same five design principles recur wherever a financing system works well: simplicity, aligned incentives, transparency, accountability, and coherence. They name no political side — a single-payer system can satisfy or fail them, and so can a system of competing, regulated private insurers. They're offered as a shared yardstick, not a verdict handed down in advance: measured against American healthcare financing as it exists today, the system falls short on nearly all five.
That is the throughline connecting every investigation on this site — from a single pharmacy receipt, to the machinery of denial and consolidation behind it, to the public-health institutions strained under separate political pressure, to what the evidence says a better-designed system would actually look like.
Ready to go deeper?